Fluidigm and Integragen join forces to create a genetic analysis service and European demonstration lab
Fluidigm has joined with IntegraGen SA to bring integrated fluidic circuits (IFC) technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm systems. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.
“With this wonderful partnership, researchers will be able to immediately utilize IntegraGen’s premiere services based on Fluidigm technology and enjoy the benefits of integrated fluidic circuits. In addition, Fluidigm will have a demonstration site for our European customers to observe and understand our easy workflow and other unique capabilities of our technology,” said Dominique Remy-Renou, Fluidigm's Vice President of European Sales and Support.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

An unexpected bonus – blocking STAT3 could help cancer patients in two ways

Fertilizing the ocean to store carbon dioxide - Iron-based fertilizer, engineered into nanoparticles, could help store excess carbon dioxide in the ocean
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) - Mailand, Italy

Drug manufacturer Dermapharm invests millions in CORAT Therapeutics - Further development of the SARS-CoV-2 antibody COR-101, which is currently in the clinical phase

Sophisticated gene memory: Researchers develop new method to genetically compare hundreds of animal species

The Achilles heel of the Coronavirus - Frameshifting as possible target for antiviral drug development
EIF and K.U.Leuven announce milestone partnership
